Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 8 |
| List of Tables | 7 | 3 |
| List of Figures | 10 | 2 |
| Blood Disorders Therapeutics Market to 2017 - Introduction | 12 | 1 |
| GBI Research Report Guidance | 12 | 1 |
| Blood Disorders Therpauetics Market to 2017 - Market Overview | 13 | 10 |
| Introduction | 13 | 1 |
| Revenue | 13 | 2 |
| Branded Vs Generics | 15 | 1 |
| Annual Cost of Treatment | 16 | 1 |
| Treatment Usage Patterns | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 19 | 1 |
| Prescription Population | 19 | 1 |
| Market Drivers | 19 | 1 |
| Steady Increase in the Prevalence Population, Particularly in the Top Five Countries of Europe | 19 | 1 |
| Rapid Uptake of Recombinant Products and Biologics due to Better Efficacy, Safety and Convenient Dosing | 19 | 1 |
| Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable | 20 | 1 |
| Increase in Blood Disorders Causing Conditions such as Cancer and Cardiovascular Events | 20 | 1 |
| Market Restraints | 21 | 1 |
| Low Diagnosis Rate as the Contemporary Diagnostic Tools Unable to Diagnose Most Severe Forms of Blood Disorders | 21 | 1 |
| Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market | 21 | 1 |
| Clearance of the Regulatory Pathway in the US Will Open up the World s Largest Pharmaceutical Market to Biosimilar Players | 21 | 1 |
| Sluggish Growth in the Annual Cost of Treatment for Blood Disorders is Expected to Drive Down the Growth Rate | 22 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Geographical Landscape | 23 | 18 |
| Geographical Break-up | 23 | 2 |
| The US | 25 | 1 |
| Revenue | 25 | 1 |
| Annual Cost of Treatment | 26 | 1 |
| Treatment Usage Patterns | 27 | 1 |
| Diseased Population | 28 | 1 |
| Treatment Seeking Population | 28 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 29 | 1 |
| Top Five Countries of Europe | 30 | 1 |
| Revenue | 30 | 1 |
| Country Segmentation | 31 | 2 |
| Annual Cost of Treatment | 33 | 1 |
| Treatment Usage Patterns | 34 | 1 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 35 | 1 |
| Diagnosed Population | 36 | 1 |
| Prescription Population | 36 | 1 |
| Japan | 37 | 1 |
| Revenue | 37 | 1 |
| Annual Cost of Treatment | 38 | 1 |
| Treatment Usage Patterns | 39 | 1 |
| Diseased Population | 40 | 1 |
| Treatment Seeking Population | 40 | 1 |
| Diagnosed Population | 40 | 1 |
| Prescription Population | 40 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Therapeutic Landscape | 41 | 69 |
| Thrombosis Market | 41 | 1 |
| Introduction | 41 | 1 |
| Revenue | 41 | 2 |
| Geographic Segmentation | 43 | 1 |
| Branded Vs Generics | 44 | 1 |
| Annual Cost of Treatment | 45 | 1 |
| Treatment Flow Algorithm | 46 | 1 |
| Treatment Usage Patterns | 47 | 1 |
| Diseased Population | 48 | 1 |
| Treatment Seeking Population | 48 | 1 |
| Diagnosed Population | 49 | 1 |
| Prescription Population | 49 | 1 |
| Anemia Market | 49 | 1 |
| Introduction | 49 | 1 |
| Revenue | 50 | 1 |
| Geographic Segmentation | 51 | 2 |
| Branded Vs Generics | 53 | 1 |
| Annual Cost of Treatment | 54 | 1 |
| Treatment Flow Algorithm | 55 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Diseased Population | 57 | 1 |
| Treatment Seeking Population | 57 | 1 |
| Diagnosed Population | 58 | 1 |
| Prescription Population | 58 | 1 |
| Neutropenia Market | 59 | 1 |
| Introduction | 59 | 1 |
| Revenue | 60 | 1 |
| Geographic Segmentation | 61 | 1 |
| Branded Vs Generics | 62 | 1 |
| Annual Cost of Treatment | 63 | 1 |
| Treatment Flow Algorithm | 64 | 1 |
| Treatment Usage Patterns | 65 | 1 |
| Diseased Population | 66 | 1 |
| Treatment Seeking Population | 66 | 1 |
| Diagnosed Population | 66 | 1 |
| Prescription Population | 67 | 1 |
| Hemophilia A Market | 67 | 1 |
| Introduction | 67 | 1 |
| Revenue | 68 | 2 |
| Geographic Segmentation | 70 | 1 |
| Branded Vs Generics | 71 | 1 |
| Annual Cost of Treatment | 72 | 1 |
| Treatment Flow Algorithm | 73 | 1 |
| Treatment Usage Patterns | 74 | 1 |
| Diseased Population | 75 | 1 |
| Treatment Seeking Population | 75 | 1 |
| Diagnosed Population | 76 | 1 |
| Prescription Population | 76 | 1 |
| Hemophilia B Market | 76 | 1 |
| Introduction | 76 | 1 |
| Revenue | 77 | 2 |
| Geographic Segmentation | 79 | 1 |
| Branded Vs Generics | 80 | 1 |
| Annual Cost of Treatment | 81 | 1 |
| Treatment Flow Algorithm | 82 | 1 |
| Treatment Usage Patterns | 83 | 1 |
| Diseased Population | 84 | 1 |
| Treatment Seeking Population | 84 | 1 |
| Diagnosed Population | 85 | 1 |
| Prescription Population | 85 | 1 |
| Hemophilia C Market | 85 | 1 |
| Introduction | 85 | 1 |
| Revenue | 86 | 1 |
| Geographic Segmentation | 87 | 1 |
| Branded Vs Generics | 88 | 1 |
| Annual Cost of Treatment | 89 | 1 |
| Treatment Flow Algorithm | 90 | 1 |
| Treatment Usage Patterns | 91 | 1 |
| Diseased Population | 92 | 1 |
| Treatment Seeking Population | 92 | 1 |
| Diagnosed Population | 92 | 1 |
| Prescription Population | 92 | 1 |
| von Willebrand s Disease (vWD) Market | 93 | 1 |
| Introduction | 93 | 1 |
| Revenue | 94 | 1 |
| Geographic Segmentation | 95 | 1 |
| Branded Vs Generics | 96 | 1 |
| Annual Cost of Treatment | 97 | 1 |
| Treatment Flow Algorithm | 98 | 1 |
| Treatment Usage Patterns | 99 | 1 |
| Diseased Population | 100 | 1 |
| Treatment Seeking Population | 100 | 1 |
| Diagnosed Population | 100 | 1 |
| Prescription Population | 100 | 1 |
| Alexander s Disease (Factor VII Deficiency) Market | 101 | 1 |
| Introduction | 101 | 1 |
| Revenue | 101 | 2 |
| Geographic Segmentation | 103 | 1 |
| Branded Vs Generics | 104 | 1 |
| Annual Cost of Treatment | 105 | 1 |
| Treatment Flow Algorithm | 106 | 1 |
| Treatment Usage Patterns | 107 | 1 |
| Diseased Population | 108 | 1 |
| Treatment Seeking Population | 108 | 1 |
| Diagnosed Population | 108 | 1 |
| Prescription Population | 109 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Pipeline Analysis | 110 | 16 |
| Introduction | 110 | 1 |
| Research and Development Pipeline Thrombosis | 111 | 2 |
| Research and Development Pipeline Anemia | 113 | 2 |
| Research and Development Pipeline Neutropenia | 115 | 2 |
| Research and Development Pipeline Hemophilia | 117 | 3 |
| Research and Development Pipeline von Willebrand Disease (vWD) | 120 | 1 |
| Research and Development Pipeline Alexander s Disease | 121 | 1 |
| Profiles of Promisisng Molecules in the Blood Disorders Market | 121 | 1 |
| Brilinta/Brilique | 121 | 1 |
| Introduction | 121 | 1 |
| Mechanism of Action | 121 | 1 |
| Clinical Trial Management | 121 | 1 |
| R744 | 122 | 1 |
| Introduction | 122 | 1 |
| Mechanism of Action | 122 | 1 |
| Clinical Trial Management | 122 | 1 |
| VGX-3200 | 123 | 1 |
| Introduction | 123 | 1 |
| Mechanism of Action | 123 | 1 |
| Clinical Trial Management | 123 | 1 |
| Nupen | 124 | 1 |
| Introduction | 124 | 1 |
| Mechanism of Action | 124 | 1 |
| Clinical Trial Management | 124 | 1 |
| NecLip-pdFVIII | 125 | 1 |
| Introduction | 125 | 1 |
| Mechanism of Action | 125 | 1 |
| Clinical Trial Management | 125 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Competitive Landscape | 126 | 9 |
| Market Share Analysis: Blood Disorders | 126 | 1 |
| Competitive Profiling | 126 | 1 |
| Amgen | 126 | 1 |
| Company Overview | 126 | 1 |
| Product Portfolio | 126 | 2 |
| SWOT Analysis | 128 | 1 |
| Bristol-Myers Squibb | 128 | 1 |
| Company Overview | 128 | 1 |
| Product Portfolio | 128 | 1 |
| SWOT Analysis | 129 | 1 |
| Sanofi | 130 | 1 |
| Company Overview | 130 | 1 |
| Product Portfolio | 130 | 1 |
| SWOT Analysis | 131 | 1 |
| Baxter International Inc. | 132 | 1 |
| Company Overview | 132 | 1 |
| Product Portfolio | 132 | 1 |
| SWOT Analysis | 133 | 1 |
| Centocor Ortho Biotech Inc. | 133 | 1 |
| Company Overview | 133 | 1 |
| Product Portfolio | 134 | 1 |
| SWOT Analysis | 134 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Strategic Consolidations | 135 | 9 |
| M&A Deals | 135 | 1 |
| Deals by Indication | 135 | 1 |
| Deals by Geography | 136 | 1 |
| Deals by Value | 137 | 1 |
| Major M&A Deals | 138 | 1 |
| GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 2009 | 139 | 1 |
| Biovitrum AB Acquired Swedish Orphan International AB in November 2009 | 139 | 1 |
| Pfizer Acquired Wyeth in January 2009 | 139 | 1 |
| Baxter International to Acquire Hemophilia-Related Assets from Archemix in November 2010 | 139 | 1 |
| Paul Capital Healthcare Acquires Rights to Xyntha from Dyax in April 2010 | 140 | 1 |
| Baxter Healthcare Acquires Rights to AV513 from Avigen in December 2008 | 140 | 1 |
| Bayer HealthCare Acquires MAXY-VII from Maxygen in July 2008 | 140 | 1 |
| Accredo Health Acquires Hemophilia Resources of America in July 2004 | 140 | 1 |
| CSL Acquires Aventis Behring from Aventis in March 2004 | 140 | 1 |
| Licensing Agreements | 141 | 1 |
| Deals by Indication | 141 | 1 |
| Deals by Geography | 142 | 1 |
| Deals by Value ($) | 143 | 1 |
| Blood Disorders Therapeutics Market to 2017 - Appendix | 144 | 8 |
| Market Definitions | 144 | 1 |
| Abbreviations | 144 | 1 |
| Research Methodology | 145 | 2 |
| Coverage | 145 | 1 |
| Secondary Research | 145 | 1 |
| Primary Research | 146 | 1 |
| Therapeutic Landscape | 146 | 3 |
| Epidemiology-based Forecasting | 147 | 1 |
| Market Size by Geography | 148 | 1 |
| Geographical Landscape | 149 | 1 |
| Pipeline Analysis | 149 | 1 |
| Competitive Landscape | 149 | 1 |
| Expert Panel Validation | 149 | 1 |
| Contact Us | 149 | 1 |
| Disclaimer | 150 | 1 |
| Sources | 150 | 2 |